NewAmsterdam Pharma Company N.V. (NAMS)

NAMS Revenue

NewAmsterdam Pharma Company had revenue of $3.04M in the quarter ending March 31, 2026, with 2.08% growth. This brings the company's revenue in the last twelve months to $22.57M, down -52.13% year-over-year. In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%.

• Revenue (ttm): $22.57M
• Revenue Growth: -52.13%
• P/S Ratio: 157.50
• Revenue / Employee: $225,650
• Employees: 100
• Market Cap: 3.55B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	22.50M	-23.06M	-50.61%
Dec 31, 2024	45.56M	31.47M	223.37%
Dec 31, 2023	14.09M	-88.60M	-86.28%
Dec 31, 2022	102.69M	-	-
Dec 31, 2021	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Feb 18, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 13, 2026

Data Sources Report a data error